These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 15545668

  • 1. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
    Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson LC, Franssila K, Nupponen NN, Joensuu H.
    J Clin Oncol; 2005 Jan 01; 23(1):49-57. PubMed ID: 15545668
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.
    Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A, Hagemeijer A, Sciot R.
    J Pathol; 2004 Apr 01; 202(4):430-8. PubMed ID: 15095270
    [Abstract] [Full Text] [Related]

  • 3. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN.
    J Pathol; 2005 Oct 01; 207(2):224-31. PubMed ID: 16021678
    [Abstract] [Full Text] [Related]

  • 4. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours.
    Sihto H, Franssila K, Tanner M, Vasama-Nolvi C, Sarlomo-Rikala M, Nupponen NN, Joensuu H, Isola J.
    Scand J Gastroenterol; 2006 Jul 01; 41(7):805-11. PubMed ID: 16785193
    [Abstract] [Full Text] [Related]

  • 5. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles.
    Subramanian S, West RB, Corless CL, Ou W, Rubin BP, Chu KM, Leung SY, Yuen ST, Zhu S, Hernandez-Boussard T, Montgomery K, Nielsen TO, Patel RM, Goldblum JR, Heinrich MC, Fletcher JA, van de Rijn M.
    Oncogene; 2004 Oct 14; 23(47):7780-90. PubMed ID: 15326474
    [Abstract] [Full Text] [Related]

  • 6. Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach.
    Cho S, Kitadai Y, Yoshida S, Tanaka S, Yoshihara M, Yoshida K, Chayama K.
    Int J Oncol; 2006 Jun 14; 28(6):1361-7. PubMed ID: 16685437
    [Abstract] [Full Text] [Related]

  • 7. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
    Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I, Estevez-Schwarz L, Mawrin C, Friedrich RE, Mautner VF, von Deimling A.
    Carcinogenesis; 2006 Mar 14; 27(3):664-71. PubMed ID: 16357008
    [Abstract] [Full Text] [Related]

  • 8. PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors.
    Miselli F, Millefanti C, Conca E, Negri T, Piacenza C, Pierotti MA, Tamborini E, Pilotti S.
    Am J Surg Pathol; 2008 May 14; 32(5):738-43. PubMed ID: 18360281
    [Abstract] [Full Text] [Related]

  • 9. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
    Du CY, Shi YQ, Zhou Y, Fu H, Zhao G.
    J Surg Oncol; 2008 Sep 01; 98(3):175-8. PubMed ID: 18618605
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E, Merkelbach-Bruse S, Büttner R, Schildhaus HU.
    Verh Dtsch Ges Pathol; 2007 Sep 01; 91():165-8. PubMed ID: 18314611
    [Abstract] [Full Text] [Related]

  • 12. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S, Chen LR, Wang HJ, Chen SZ.
    Hepatogastroenterology; 2007 Dec 01; 54(80):2285-90. PubMed ID: 18265649
    [Abstract] [Full Text] [Related]

  • 13. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J, Miettinen M.
    Histopathology; 2008 Sep 01; 53(3):245-66. PubMed ID: 18312355
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Therapeutic targets in gastrointestinal stromal tumors].
    Wardelmann E, Schildhaus HU, Merkelbach-Bruse S, Büttner R.
    Verh Dtsch Ges Pathol; 2006 Sep 01; 90():73-9. PubMed ID: 17867582
    [Abstract] [Full Text] [Related]

  • 17. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
    Andersson J, Bümming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, Odén A, Gustavsson B, Kindblom LG, Nilsson B.
    Gastroenterology; 2006 May 01; 130(6):1573-81. PubMed ID: 16697720
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Diagnostic relevance of overexpressions of PKC-θ and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases.
    Kim KH, Nelson SD, Kim DH, Choi KU, Kim SJ, Min KW, Jang KS, Paik SS, Oh YH, Chae SW, Sohn JH, Kim HJ, Cho YK, Kim BI, Park DI, Sohn CI, Oh S, Choi SH, Choi YJ, Woo HY, Park YL, Park SJ, Lee SH, Ryu S, DO SI, Kang G, Kim K, Cho YH, Pyo JS.
    Anticancer Res; 2012 Mar 01; 32(3):923-37. PubMed ID: 22399613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.